Insider · CIK 0001808895
Bernard Coulie
Files at PLRX (PLIANT THERAPEUTICS, INC.), SEPN (Septerna, Inc.). First filing Jan 22, 2025, latest Jan 22, 2026.
Bernard Coulie files SEC Form 4 as CEO, president and director at PLRX (PLIANT THERAPEUTICS, INC.), and also at SEPN (Septerna, Inc.). Since Jan 22, 2025, Bernard Coulie has reported 0 open-market buys worth $0 and 2 open-market sells worth $702k, the latest filed on Jan 22, 2026.
A track record needs three past buys with six months of prices behind them; Bernard Coulie has 0, so none is measured yet.
The newest scored trade: sold $114k of PLRX on Jan 20, 2026, filed Jan 22, 2026, scored 35 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $114k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PLRX: PLIANT THERAPEUTICS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 35Weak | PLIANT THERAPEUTICS, INC. | $114k 89,375 shares | -15% | +10% from low-90% from high | |
| 44Moderate | PLIANT THERAPEUTICS, INC. | $587k 52,419 shares | -11% | - |
Transactions
Every row this insider has filed, 21 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | SEPN Septerna, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +15,000 | $0.00 | $0 | 15,000 | Jun 30, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -146,841 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +146,841 | $0.00 | $0 | 146,841 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -327,262 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +327,262 | $0.00 | $0 | 327,262 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -250,000 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -440,000 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +440,000 | $0.00 | $0 | 440,000 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -206,300 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +206,300 | $0.00 | $0 | 206,300 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -256,300 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +256,300 | $0.00 | $0 | 256,300 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | DDisposition to issuer Stock Option (Right to Buy)derivative | -325,000 | $0.00 | $0 | 0 | Apr 17, 2026 |
| Apr 17, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Apr 17, 2026 |
| Jan 22, 2026 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,230,000 | $0.00 | $0 | 1,230,000 | Jan 26, 2026 |
| Jan 20, 2026 | PLRX PLIANT THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -89,375 | $1.28 | $114k | 505,601 | Jan 22, 2026 |
| Jun 17, 2025 | SEPN Septerna, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +16,623 | $0.00 | $0 | 16,623 | Jun 20, 2025 |
| Jan 23, 2025 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Common Stock | +162,500 | $0.00 | $0 | 593,017 | Jan 27, 2025 |
| Jan 23, 2025 | PLRX PLIANT THERAPEUTICS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +325,000 | $0.00 | $0 | 325,000 | Jan 27, 2025 |
| Jan 17, 2025 | PLRX PLIANT THERAPEUTICS, INC. | SOpen-market sale Common Stock10b5-1 | -52,419 | $11.20 | $587k | 430,517 | Jan 22, 2025 |
Questions about Bernard Coulie
Answered from the filings on this page, as of the latest one.
Is Bernard Coulie buying or selling?
In the last 12 months Bernard Coulie reported 0 open-market buys worth $0 and 1 open-market sell worth $114k on SEC Form 4; the latest was sold $114k of PLRX on Jan 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Bernard Coulie's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Bernard Coulie has 0.
Where does Bernard Coulie file Form 4?
Bernard Coulie has filed Form 4 at PLRX (PLIANT THERAPEUTICS, INC.) as President and CEO; SEPN (Septerna, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.